MX2023010850A - Restos patógenos y usos de los mismos. - Google Patents
Restos patógenos y usos de los mismos.Info
- Publication number
- MX2023010850A MX2023010850A MX2023010850A MX2023010850A MX2023010850A MX 2023010850 A MX2023010850 A MX 2023010850A MX 2023010850 A MX2023010850 A MX 2023010850A MX 2023010850 A MX2023010850 A MX 2023010850A MX 2023010850 A MX2023010850 A MX 2023010850A
- Authority
- MX
- Mexico
- Prior art keywords
- moieties
- neisseria
- pathogen
- disclosure relates
- lipooligosaccharides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Gram-negative bacteria
- C07K16/1217—Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163161399P | 2021-03-15 | 2021-03-15 | |
| PCT/AU2022/050213 WO2022192937A1 (en) | 2021-03-15 | 2022-03-14 | Pathogen moieties and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010850A true MX2023010850A (es) | 2023-12-15 |
Family
ID=83321844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010850A MX2023010850A (es) | 2021-03-15 | 2022-03-14 | Restos patógenos y usos de los mismos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240156970A1 (https=) |
| EP (1) | EP4308155A4 (https=) |
| JP (1) | JP2024510334A (https=) |
| KR (1) | KR20240004299A (https=) |
| CN (1) | CN117377484A (https=) |
| AU (1) | AU2022241364A1 (https=) |
| BR (1) | BR112023018748A2 (https=) |
| CA (1) | CA3212271A1 (https=) |
| MX (1) | MX2023010850A (https=) |
| WO (1) | WO2022192937A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2264970A1 (en) * | 1998-03-10 | 1999-09-10 | American Cyanamid Company | Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria |
| EP2573100A1 (en) * | 2011-09-23 | 2013-03-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Total synthesis of the core tetrasaccharide of the lipopolysaccharide from Neisseria meningitidis |
| PL404229A1 (pl) * | 2013-06-06 | 2014-12-08 | Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością | Wyizolowany immunogenny antygen bakteryjny i jego zastosowanie w profilaktyce i leczeniu zakażeń wywołanych przez Gram-ujemne bakterie |
| WO2016007891A1 (en) * | 2014-07-10 | 2016-01-14 | University Of Iowa Research Foundation | Vaccine for nontypeable haemophilus influenzae |
-
2022
- 2022-03-14 AU AU2022241364A patent/AU2022241364A1/en active Pending
- 2022-03-14 WO PCT/AU2022/050213 patent/WO2022192937A1/en not_active Ceased
- 2022-03-14 BR BR112023018748A patent/BR112023018748A2/pt unknown
- 2022-03-14 US US18/550,659 patent/US20240156970A1/en active Pending
- 2022-03-14 CN CN202280035329.4A patent/CN117377484A/zh active Pending
- 2022-03-14 JP JP2023557756A patent/JP2024510334A/ja active Pending
- 2022-03-14 MX MX2023010850A patent/MX2023010850A/es unknown
- 2022-03-14 CA CA3212271A patent/CA3212271A1/en active Pending
- 2022-03-14 KR KR1020237034995A patent/KR20240004299A/ko active Pending
- 2022-03-14 EP EP22770065.5A patent/EP4308155A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240156970A1 (en) | 2024-05-16 |
| AU2022241364A1 (en) | 2023-10-05 |
| BR112023018748A2 (pt) | 2023-11-28 |
| EP4308155A4 (en) | 2025-03-05 |
| CA3212271A1 (en) | 2022-09-22 |
| KR20240004299A (ko) | 2024-01-11 |
| JP2024510334A (ja) | 2024-03-06 |
| EP4308155A1 (en) | 2024-01-24 |
| CN117377484A (zh) | 2024-01-09 |
| WO2022192937A1 (en) | 2022-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4592314A3 (en) | Single-chain and multi-chain chimeric polypeptides and uses thereof | |
| AU2017382297A8 (en) | Phosphodiesterase inhibitors and methods of microbial treatment | |
| SA519402400B1 (ar) | تركيبات وطرق لعلاج أمراض الهيموجلوبين | |
| WO2019224716A8 (en) | Antibodies specific for gucy2c and uses thereof | |
| MX2018000147A (es) | Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45). | |
| EP4234708A3 (en) | Integrated fermentation and electrolysis process | |
| PH12013501074A1 (en) | Compositions and methods for treatment of microbial disorders | |
| EP4635568A3 (en) | Compounds, salts thereof and methods for treatment of diseases | |
| EA201890315A1 (ru) | Молекулы антител, связывающие cd22 | |
| WO2020051375A3 (en) | Papd5 inhibitors and methods of use thereof | |
| WO2018146557A3 (en) | Long double-stranded rna for rna interference | |
| MX2020003219A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
| PH12022550130A1 (en) | Enzyme inhibitors | |
| MX2021015766A (es) | Nuevos antigenos y metodos contra el cancer. | |
| WO2018128826A8 (en) | Compositions and methods for the treatment of bacterial infections | |
| WO2019111115A3 (en) | Human milk oligosaccharides for treating migraine | |
| MX2021006682A (es) | Inhibidores de descarboxilasa para el tratamiento de la enfermedad de parkinson. | |
| PL409078A1 (pl) | Sposób otrzymywania 4-metylo-α,β-dihydrochalkonu | |
| PL409077A1 (pl) | Sposób otrzymywania 4'-metoksy-α, β-dihydrochalkonu | |
| PL409076A1 (pl) | Sposób otrzymywania 4'-metoksy-4-metylo-α, β-dihydrochalkonu | |
| ZA202106807B (en) | Antibodies having specificity for btn2 and uses thereof | |
| BR112017016194A2 (pt) | método | |
| MX2023010850A (es) | Restos patógenos y usos de los mismos. | |
| MA39831A (fr) | Biocide pour boues | |
| AR117094A1 (es) | Moduladores de expresión irf5 |